Celebrating a new era of diagnostic innovation
29 Aug 2024
Join Beckman Coulter Diagnostics as it enters an exciting era of clinical innovation. The company's new President, Kevin O’Reilly, shares his vision for advancing Beckman Coulter Diagnostics with groundbreaking technologies like the award-winning DxI 9000.
Discover how Beckman Coulter is revolutionizing clinical diagnostics through enhanced reliability, automation, and workflow efficiency. Learn about the company's commitment to making significant clinical impacts, including the development of a blood-based Alzheimer's biomarker test.
This video was filmed at ADLM 2024 and is shared as part of the global CLINICAL24 conversation. .
About the company
Beckman Coulter Diagnostics
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents approximately 78 percent of the company s 2007 annual revenue of $2.76 billion. For more information, visit www.beckmancoulter.com.
Related products
Request Quote for All Products
DxI 9000 Access Immunoassay Analyzer
Beckman Coulter DiagnosticsThe award-winning DxI 9000 Analyzer sets a new standard for today’s busy labs. With meaningful innovations that amplify your impact, liberate you from the laborious, and power your performance across your health system, this high-throughput immunoassay analyzer takes diagnostics to the next level.
